🇺🇸 FDA
Pipeline program

Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion

IMMU-132-13

Phase 3 small_molecule active

Quick answer

Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion for Locally Advanced or Metastatic Unresectable Urothelial Cancer is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Gilead Sciences International Limited
Indication
Locally Advanced or Metastatic Unresectable Urothelial Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials